Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Differential Expression of Down-regulated MicroRNA-126 and Micro RNA-22 in Ovarian Carcinogenesis

Author(s): Nidhi Paliwal, Minakshi Vashist*, Meenakshi Chauhan, Geetanjali Yadav, Suman Deshwal and Kiran Siwach

Volume 20, Issue 3, 2024

Published on: 24 May, 2023

Article ID: e270423216273 Pages: 10

DOI: 10.2174/1573404820666230427121703

Price: $65

Abstract

Background: Non-coding RNA i.e. MicroRNA plays an important role in the progression and pathogenesis of different types of tumours including ovarian cancer. Deregulated microRNA expression could transform the passivity of cancer, disease progression, chemoresistance, and mobility. The miRNA profile of healthy and cancerous samples was observed to be different. MicroRNA expression analysis and profiling have a bright future in improving the effectiveness of ovarian cancer treatment that is customized to the patient's specific requirements. Expression analysis of serum microRNA- 126 and microRNA-22 in ovarian carcinogenesis has been done in the present study.

Methods: Present study has been done in the serum of eighty- two epithelial ovarian cancer patients and eighty- two their age-matched healthy women to investigate +the expression of miR-126 and miR- 22 was TaqMan PCR microRNA assay. The correlation of expression miR-126 and miR-22 with epidemiological and clinicopathological factors was determined statistically.

Results: Results showed a 3.37-fold decrease in miR-126 expression and a 2.67-fold reduction in miR-22 expression in ovarian cancer patients. Decreased serum level of miR-22 and miR-126 in ovarian cancer patients has been correlated with the FIGO stage. Results revealed 87.46 sensitivity and 91.12 specificities for down-regulated microRNA 22 with FIGO stage of ovarian cancer and 71.26 sensitivity and 81.12 specificities respectively. More sensitivity and specificity of microRNA 22 with FIGO stage of ovarian cancer was revealed as compared to microRNA 126.

Conclusion: Present study revealed downregulated expression of miR-126 and miR-22 in the serum of epithelial ovarian cancer patients. Among all epidemiological and clinical parameters, the FIGO stage of ovarian cancer revealed a substantial association with microRNA level. Results revealed that the sensitivity and specificity of down-regulated microRNA 22 in ovarian cancer were 87.46 and 91.12 and for microRNA 126 with 71.26 and 81.12 respectively. This may be investigated and verified as a durable diagnostic biomarker for the pre-diagnosis of ovarian carcinogenesis.

Graphical Abstract

[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin., 2020, 70(1), 7-30.
[http://dx.doi.org/10.3322/caac.21590] [PMID: 31912902]
[2]
WHO: World Health Statistics. Monitoring Health for the SDGs; World Health Organization: Geneva, Switzerland, 2019.
[3]
Mathur, P.; Sathishkumar, K.; Chaturvedi, M.; Das, P.; Sudarshan, K.L.; Santhappan, S.; Nallasamy, V.; John, A.; Narasimhan, S.; Roselind, F.S. Cancer Statistics, 2020: Report from national cancer registry programme, India. JCO Glob. Oncol., 2020, 6(6), 1063-1075.
[http://dx.doi.org/10.1200/GO.20.00122] [PMID: 32673076]
[4]
NCI Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovarian Cancer. Available from: https://seer.cancer.gov/statfacts/html/ovary.html (Accessed on: 14 October 2019).
[5]
Torre, L.A.; Trabert, B.; DeSantis, C.E.; Miller, K.D.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(4), 284-296.
[http://dx.doi.org/10.3322/caac.21456] [PMID: 29809280]
[6]
Qu, H.; Xu, W.; Huang, Y.; Yang, S. Circulating miRNAs: Promising biomarkers of human cancer. Asian Pac. J. Cancer Prev., 2011, 12(5), 1117-1125.
[PMID: 21875254]
[7]
Martin, D.; Jansson, ; Anders, H.; Lund, Micro RNA and Cancer. Mol. Oncol., 2012, 6, 590-610.
[8]
Zhang, W.; Dahlberg, J.E.; Tam, W. MicroRNAs in tumorigenesis. Am. J. Pathol., 2007, 171(3), 728-738.
[http://dx.doi.org/10.2353/ajpath.2007.070070] [PMID: 17724137]
[9]
Bandyopadhyay, S.; Mitra, R.; Maulik, U.; Zhang, M.Q. Development of the human cancer microRNA network. Silence, 2010, 1(1), 6.
[http://dx.doi.org/10.1186/1758-907X-1-6] [PMID: 20226080]
[10]
Pepin, K.; Carmen, M.; Brown, A.; Dizon, D.S. CA 125 and epithelial ovarian cancer: Role in screening, diagnosis and surveillance. Am. J. Hematol. Oncol., 2014, 10(6), 22-29.
[11]
National cancer registry programme (2016). Incidence and distribution of cancer, Bangalore, India. In: Indian council of medical research, two-year report of population based cancer registries; , 2016.
[12]
Woolas, R.P.; Xu, F.J.; Jacabs, I.J.; Yu, Y.H.; Daly, L.; Brechuck, A.; Soper, J.T.; Clarke-pearson, D.L.; Oram, D.H.; Bast, R.C., Jr Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl. Cancer Inst., 1993, 85(21), 1748-1751.
[http://dx.doi.org/10.1093/jnci/85.21.1748] [PMID: 8411259]
[13]
Jacobs, I.; Bast, R.C., Jr The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod., 1989, 4(1), 1-12.
[http://dx.doi.org/10.1093/oxfordjournals.humrep.a136832] [PMID: 2651469]
[14]
Menon, U.; Jacobs, I.J. Recent developments in ovarian cancer screening. Curr. Opin. Obstet. Gynecol., 2000, 12(1), 39-42.
[http://dx.doi.org/10.1097/00001703-200002000-00007] [PMID: 10752515]
[15]
Jacobs, I.J.; Menon, U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics, 2004, 3(4), 355-366.
[http://dx.doi.org/10.1074/mcp.R400006-MCP200] [PMID: 14764655]
[16]
Munkarah, A.; Chatterjee, M.; Tainsky, M.A. Update on ovarian cancer screening. Curr. Opin. Obstet. Gynecol., 2007, 19(1), 22-26.
[http://dx.doi.org/10.1097/GCO.0b013e328011ec99] [PMID: 17218847]
[17]
Halushka, M.K.; Fromm, B.; Peterson, K.J.; McCall, M.N. Big strides in cellular microRNA expression. Trends Genet., 2018, 34(3), 165-167.
[http://dx.doi.org/10.1016/j.tig.2017.12.015] [PMID: 29361313]
[18]
Juzenas, S.; Venkatesh, G.; Hübenthal, M.; Hoeppner, M.P.; Du, Z.G.; Paulsen, M.; Rosenstiel, P.; Senger, P.; Hofmann-Apitius, M.; Keller, A.; Kupcinskas, L.; Franke, A.; Hemmrich-Stanisak, G. A comprehensive, cell specific microRNA catalogue of human peripheral blood. Nucleic Acids Res., 2017, 45(16), 9290-9301.
[http://dx.doi.org/10.1093/nar/gkx706] [PMID: 28934507]
[19]
Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; Li, Q.; Li, X.; Wang, W.; Zhang, Y.; Wang, J.; Jiang, X.; Xiang, Y.; Xu, C.; Zheng, P.; Zhang, J.; Li, R.; Zhang, H.; Shang, X.; Gong, T.; Ning, G.; Wang, J.; Zen, K.; Zhang, J.; Zhang, C.Y. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 2008, 18(10), 997-1006.
[http://dx.doi.org/10.1038/cr.2008.282] [PMID: 18766170]
[20]
Farr, R.J.; Januszewski, A.S.; Joglekar, M.V.; Liang, H.; McAulley, A.K.; Hewitt, A.W.; Thomas, H.E.; Loudovaris, T.; Kay, T.W.H.; Jenkins, A.; Hardikar, A.A. A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci. Rep., 2015, 5(1), 10375.
[http://dx.doi.org/10.1038/srep10375] [PMID: 26035063]
[21]
Häusler, S F M.; Keller, A.; Chandran, P.A.; Ziegler, K.; Zipp, K.; Heuer, S.; Krockenberger, M.; Engel, J.B.; Hönig, A.; Scheffler, M.; Dietl, J.; Wischhusen, J. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br. J. Cancer, 2010, 103(5), 693-700.
[http://dx.doi.org/10.1038/sj.bjc.6605833] [PMID: 20683447]
[22]
Kobayashi, M.; Sawada, K.; Nakamura, K.; Yoshimura, A.; Miyamoto, M.; Shimizu, A.; Ishida, K.; Nakatsuka, E.; Kodama, M.; Hashimoto, K.; Mabuchi, S.; Kimura, T. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. J. Ovarian Res., 2018, 11(1), 81.
[http://dx.doi.org/10.1186/s13048-018-0458-0] [PMID: 30219071]
[23]
Wan, W.; Zhang, Y.; Wang, X.; Liu, Y.; Zhang, Y.; Que, Y.; Zhao, W.; Li, P. Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer. Diagn. Pathol., 2014, 9(1), 178.
[http://dx.doi.org/10.1186/s13000-014-0178-8] [PMID: 25257702]
[24]
Agostini, A.; Brunetti, M.; Davidson, B.; Tropé, C.G.; Eriksson, A.G.Z.; Heim, S.; Panagopoulos, I.; Micci, F. The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. Sci. Rep., 2018, 8(1), 11069.
[http://dx.doi.org/10.1038/s41598-018-29332-7] [PMID: 30038317]
[25]
Yokoi, A.; Yoshioka, Y.; Hirakawa, A.; Yamamoto, Y.; Ishikawa, M.; Ikeda, S.; Kato, T.; Niimi, K.; Kajiyama, H.; Kikkawa, F.; Ochiya, T. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget, 2017, 8(52), 89811-89823.
[http://dx.doi.org/10.18632/oncotarget.20688] [PMID: 29163790]
[26]
Yokoi, A.; Matsuzaki, J.; Yamamoto, Y.; Yoneoka, Y.; Takahashi, K.; Shimizu, H.; Uehara, T.; Ishikawa, M.; Ikeda, S.; Sonoda, T.; Kawauchi, J.; Takizawa, S.; Aoki, Y.; Niida, S.; Sakamoto, H.; Kato, K.; Kato, T.; Ochiya, T. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat. Commun., 2018, 9(1), 4319.
[http://dx.doi.org/10.1038/s41467-018-06434-4] [PMID: 30333487]
[27]
Yan, J.; Ma, S.; Zhang, Y.; Yin, C.; Zhou, X.; Zhang, G. Potential role of microRNA-126 in the diagnosis of cancers. Medicine, 2016, 95(35), e4644.
[http://dx.doi.org/10.1097/MD.0000000000004644] [PMID: 27583885]
[28]
Yang, Y.; Song, K.; Chang, H.; Chen, L. Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer. Diagn. Pathol., 2014, 9(1), 220.
[http://dx.doi.org/10.1186/s13000-014-0220-x] [PMID: 25551621]
[29]
Cao, J.; Cai, J.; Huang, D.; Han, Q.; Yang, Q.; Li, T.; Ding, H.; Wang, Z. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol. Rep., 2013, 30(2), 701-706.
[http://dx.doi.org/10.3892/or.2013.2482] [PMID: 23708561]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy